Study summary
A HER3-targeted antibody-drug conjugate delayed growth after EGFR pills stopped working
8.3months without progression, vs 5.4 with chemotherapy
What was tested
Ruzaltatug rezetecan, an antibody-drug conjugate aimed at HER3, against pemetrexed and platinum chemotherapy after EGFR pills stopped working. Run in China.
What they found
- Median progression-free survival was 8.3 vs 5.4 months.
- Severe treatment-related side effects were similar (41% vs 39%).
- Survival results are not yet mature.
What it means
Adds HER3 to TROP2 as a target for drug-carrying antibodies after resistance.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.